Skip to content

Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis

Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02873949
Acronym
TREM
Enrollment
60
Registered
2016-08-22
Start date
2016-04-30
Completion date
2017-12-31
Last updated
2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Keywords

immunology factors, TREM, stress

Brief summary

Etiopathology of periodontitis is complex and various risk factors are known : * Bacterial factors: major risk factor. Although the presence of periodontopathogen bacteria is necessary for the onset of periodontitis, these microorganisms are not sufficient for progression of all periodontal disease. * Immune factor: host immune response modulates the disease evolution to destruction or recovery. The most studied cytokine in periodontology is IL-1 that induces various immune reactions and bone resorption directly or indirectly through the stimulation of prostaglandin E2 (PGE2) release. PGE2 activates the matrix metalloproteinases that are responsible of the degradation of bone extracellular matrix. Cytokine production, especially TNFα, IL-1β, IL-6 and IL-8, by some immune cells is modulated by new identified molecules such as Triggering Receptor Expressed on Myeloid cells (TREM) whose role in periodontitis is unknown. The purpose of this study is to compare concentrations of soluble TREM-1 and TREM-2 markers in infected sites and in healthy sites in patients affected by periodontitis. Other purposes are 1. Comparison of soluble TREM-1 and TREM-2 concentrations in healthy sites in patients affected by periodontitis and in healthy patients 2. Comparison of soluble TREM-1 and TREM-2 concentrations before and after etiologic periodontitis treatment 3. Estimation of the correlation between soluble TREM-1 and TREM-2 concentrations and clinical signs of periodontitis 4. Description of soluble TREM-1/TREM-2 ratio before and after etiologic treatment 5. Description of presence of some bacteria in sites analyzed for soluble TREM-1 and TREM-2 6. Search for the most observed bacteria in presence of high concentrations of soluble TREM-1 and TREM-2 before and after etiologic treatment 7. Evaluation of the impact of psychological stress measured through salivary cortisol level in saliva on TREM-1 and -2 expression 8. Evaluation of the impact of psychological stress through stress and anxiety auto-questionnaires (Spielberger and Cohen) on soluble TREM-1 and TREM-2 concentrations in crevicular fluid of healthy and pathologic teeth.

Interventions

BIOLOGICALCrevicular samples (1-10µl)

In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment In non-periodontitis individuals: 2 samples from 1 site

BIOLOGICALSaliva samples (1ml)
OTHEREtiologic treatment

education on oral hygiene, scaling and root planing

Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

All: * Affiliation to social security plan * Absence of refusal of patient Group 1. Periodontal patients: * Affected by moderate to severe chronic periodontitis * At least 2 distinct infected sites with periodontal pocket depth ≥ 5mm * Having not received any root planing during last 6 months before visit Group 2. Control: * No periodontitis * Consulting for dental checkup and eventually scaling

Exclusion criteria

All: * Pregnant women (change in bacterial flora) and breast-feeding * Administration of systemic antibiotherapy or any treatment influencing periodontal environment (anti-inflammatory, anti-epileptic, immune-suppressor, calcium inhibitor) during 6 months before sample collection * Patients having a pathology needing a prophylactic antibiotherapy (possibly influencing the treatment) * Teeth with periapical inflammatory lesions of endodontic origin * Person under guardianship Group 1. Periodontal patients: \- Root planing during last 6 months before visit Group 2. Control: \- Periodontitis

Design outcomes

Primary

MeasureTime frame
Average concentration (quantified with ELISA assay) of soluble TREM-1 and TREM-2 in crevicular fluid from 2 distant sites affected by periodontitis and 1 healthy site of each periodontitis patients at first consultationday 0

Secondary

MeasureTime frameDescription
Average concentration (quantified with ELISA assay) of soluble TREM-1 and TREM-2 in crevicular fluid of periodontitis patients before and after etiologic treatment of periodontitisday 0 and after 13 to 15 weeks (after etiologic treatment of periodontitis patients)Crevicular fluid from 3 sites (2 distant affected by periodontitis and 1 healthy) of periodontitis patients
Identification of periodontal bacterial floraday 0 and after 13 to 15 weeks (after etiologic treatment of periodontitis patients)The kit microIDent®plus11 (Hain, Lifesciences) allows the identification by PCR of the most pathogen periodontal bacteria.
Average concentration (quantified with ELISA assay) of soluble TREM-1 and TREM-2 in crevicular fluid from healthy sites of periodontitis patients and non-periodontitis patients at first consultationday 0Crevicular fluid from 3 sites (2 distant affected by periodontitis and 1 healthy) of periodontitis patients and from 1 healthy site of non-periodontitis patients
Psychological stress score with Spielberger State-Trait Anxiety Inventoryday 0
Quantification of salivary cortisol by ELISA to measure psychological stressday 0
Psychological stress score with Cohen Perceived Stress Scaleday 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026